Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 1—January 2003

Research

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Gillian D. Sanders*Comments to Author  and Al V. Taira*
Author affiliations: *Stanford University, Stanford, California, USA

Main Article

Figure 5

Sensitivity analysis: Frequency of Pap tests in vaccinated women. Effect of changing the frequency with which vaccinated women receive a Pap test. The diamonds represent Pap testing vaccinated women annually, every 2 years (base case), every 3 years, every 4 years, and every 5 years. The x-axis represents the lifetime expected cost of the vaccination strategy; the y-axis is the quality-adjusted life expectancy in years. The incremental cost effectiveness of increasing the frequency of Pap testin

Figure 5. Sensitivity analysis: Frequency of Pap tests in vaccinated women. Effect of changing the frequency with which vaccinated women receive a Pap test. The diamonds represent Pap testing vaccinated women annually, every 2 years (base case), every 3 years, every 4 years, and every 5 years. The x-axis represents the lifetime expected cost of the vaccination strategy; the y-axis is the quality-adjusted life expectancy in years. The incremental cost effectiveness of increasing the frequency of Pap testing for vaccinated women is indicated numerically above the cost-effectiveness frontier.

Main Article

TOP